Wealth Enhancement Advisory Services Reduces $3M in Becton, Dickinson and Company ($BDX)
Key Points
- Wealth Enhancement Advisory Services changed its Becton, Dickinson and Company ($BDX) stake by 20.03% last quarter, cutting to 91,114 shares worth $13.79 million.
- Wall Street's consensus rating on $BDX is Buy and an average price target of $194.42.
- $BDX last traded around $151.33.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Wealth Enhancement Advisory Services reduced its position in Becton, Dickinson and Company ($BDX) by 20.03% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 91,114 shares of Becton, Dickinson and Company after selling 22,824 shares during the quarter. Wealth Enhancement Advisory Services's holdings in Becton, Dickinson and Company were worth $13.79 million as of its most recent filing.
Becton, Dickinson and Company Stock Down 20.2%
Shares of Becton, Dickinson and Company ($BDX) traded around $151.33 on Saturday, down 20.2% for the day.
Becton, Dickinson and Company Earnings
Becton, Dickinson and Company Dividend
Analysts Set New Price Targets
About Becton, Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company has a strategic collaboration with ChemoGLO for the advancement of hazardous drug contamination testing in health care settings to improve the safety of health care workers. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
Get Becton, Dickinson and Company alerts
New 13F filings, insider trades, and analyst moves on $BDX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.